Vero Biotech develops Genosyl, an FDA-approved portable, tankless system that delivers a constant concentration of inhaled nitric oxide for cardiac patients in acute settings, targeting persistent pulmonary hypertension in newborns. The device is intended to eliminate the need for large nitric oxide tanks in neonatal intensive care units, which are costly and labor-intensive. Vero says it is currently generating revenue and has raised nearly $300 million to date. Company leadership reports a rapid uptake in demand for Genosyl and is focused on ramping commercial deployment. Management plans to use new funding to support continued commercial expansion, increase device-building spend, and advance other R&D initiatives. Board director Todd Brady indicated the financing will enable faster market deployment. Vero Biotech is a commercial-stage healthcare company focused on neonatal intensive care and the acute care hospital community. Its core product is the GENOSYL Delivery System (DS), a tankless, portable inhaled nitric oxide (iNO) delivery system engineered with redundant backup features, an easy-to-use interface, and portability. The third generation of the GENOSYL DS was recently approved by the FDA. The company intends to use the proceeds from its recent financing to support further development and commercialization of GENOSYL DS. Vero Biotech raised $30M in funding in a round led by Petrichor, and Petrichor partner Patrick Lally has joined the company's board. The company is led by CEO and President Brent V. Furse and is based in Atlanta, GA. Vero Biotech LLC is an Atlanta, Georgia–based biotechnology company focused on the design, development and commercialization of next‑generation products for patients with pulmonary and cardiac diseases. Led by CEO Brent V. Furse, the company developed the GENOSYL Delivery System (GENOSYL DS), an inhaled nitric oxide delivery system that is approved by the U.S. FDA. The GENOSYL DS delivers nitric oxide, a vasodilator used in care of patients with adult respiratory distress syndrome and persistent pulmonary hypertension of the neonate. The system was authorized by the FDA for expanded emergency use for patients with cardiopulmonary complications associated with COVID‑19, was granted an emergency IND for at‑home use, and is approved for interhospital transport in ground, fixed‑wing and rotary‑wing environments. The company closed a $50M senior secured term loan from Runway Growth Capital, providing additional financing. Vero Biotech was formerly known as GeNO LLC.

Total raised

$145M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Feb 2024